<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02394275</url>
  </required_header>
  <id_info>
    <org_study_id>CDI.FMT.2</org_study_id>
    <nct_id>NCT02394275</nct_id>
  </id_info>
  <brief_title>A Prospective Trial of Frozen-and-Thawed Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection</brief_title>
  <official_title>A Prospective Open-Labelled Multi-Centre Trial of Frozen-and-Thawed Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Joseph's Healthcare Hamilton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this proposal is to study the outcome of patients with recurrent&#xD;
      Clostridium Difficile Infection (CDI) treated with frozen Fecal Microbiota Transplantation&#xD;
      (FMT) in an open-labelled controlled trial. The specific objectives are to evaluate the&#xD;
      safety of FMT and to determine the clinical response, treatment failure and relapse rate in&#xD;
      patients treated with frozen-and-thawed FMT; to assess the functional health and well-being&#xD;
      of patients in each arm using the validated tool, and to determine the feasibility of&#xD;
      providing standardized FMT in multiple centres across Canada, including community hospitals.&#xD;
      The metagenomics will also be conducted from the stool samples collected from select patients&#xD;
      from each arm: pre and post treatment and the matching donors. The metagenomics data will be&#xD;
      used to determine the bacteria which may have contributed to the cure of CDI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CDI is the most frequent cause of healthcare-associated infectious diarrhea in industrialized&#xD;
      countries and affects over 300,000 patients each year in the United States. The incidence of&#xD;
      CDI has nearly tripled between 1996 and 2005 (from 31 to 84 per 100,000 patient-days) in the&#xD;
      United States. The rise in incidence has been accompanied by an increase in disease severity,&#xD;
      with mortality in up to 6.9% of cases. According to the Canadian Nosocomial Infection&#xD;
      Surveillance Program study conducted from November 1, 2004 through April 30, 2005, the&#xD;
      incidence rate of health care-associated CDI for adult patients admitted to Canadian&#xD;
      hospitals is 65 per 100,000 patient-days. The same study identified that the overall and&#xD;
      attributable mortality of patients with CDI is 16.3% and 5.7%, respectively in Canada, which&#xD;
      is similar to the US data.1,17 The associated economic burden has also been significant.&#xD;
      Nosocomial CDI increases the cost of otherwise matched hospitalizations by four-fold,&#xD;
      translating to greater than $1 billion/year (United States). Since the implementation of&#xD;
      mandatory reporting of CDI cases in September 2008 in Ontario, more than 13 health-care&#xD;
      facilities declared CDI outbreak in Ontario. There were a number of deaths directly due to&#xD;
      CDI in these outbreaks. The management of each outbreak is very costly. The direct&#xD;
      attributable costs associated with the outbreak management alone per episode per institution&#xD;
      exceeded $1 million (direct communication with a hospital chief financial officer).&#xD;
&#xD;
      There is a growing concern regarding failure of standard antimicrobial therapy. The treatment&#xD;
      failure rates for metronidazole, which is the ﬁrst line therapy for uncomplicated CDI, have&#xD;
      risen from 2.5% to greater than 18% since 2000. Recurrence rates are higher among the&#xD;
      elderly, and exceed 50% for those over the age 65.20 Recurrence rates exceed 60% for patients&#xD;
      who have failed 3 or more episodes of standard antimicrobial therapies. The vanB gene, which&#xD;
      is responsible for conferring vancomycin resistance in Enterococcus has been isolated in&#xD;
      clostridia, potentially threatening the future use of vancomycin in CDI.&#xD;
&#xD;
      Given the high failure and recurrence rates using the standard therapy, the principal&#xD;
      investigator (PI) of this research proposal has been offering FMT for patients who&#xD;
      experienced CDI for longer than 6 months despite multiple courses of metronidazole and oral&#xD;
      vancomycin therapy. She began treating patients with recurrent CDI with FMT for the following&#xD;
      reasons. First, the patients were not responding to the antibiotic treatment. Second,&#xD;
      patients may experience intolerance to metronidazole due to metallic taste, significant&#xD;
      nausea and loss of appetite, which can lead to further weight loss as patients with CDI&#xD;
      experience considerable weight loss. Also, some patients develop irreversible peripheral&#xD;
      neuropathy (nerve damage) with long term use of metronidazole. Third, some of the patients&#xD;
      with refractory CDI could not afford to continue with oral vancomycin. The cost of oral&#xD;
      vancomycin was prohibitive and they were not routinely reimbursed by the public health plan.&#xD;
      A 14-day course of oral vancomycin costs $600 and a number of the patients were on this&#xD;
      antibiotic for 6 - 18 months at a cost of $7,200 to $21,600 (personal communication with St.&#xD;
      Joseph's Healthcare Outpatient pharmacist). The cost of one FMT is approximately $100, which&#xD;
      includes the laboratory screening test and the nurse's administration time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding for long-term follow-up&#xD;
  </why_stopped>
  <start_date type="Actual">March 1, 2014</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">September 1, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>No Recurrence of CDI-related Diarrhea</measure>
    <time_frame>13 weeks</time_frame>
    <description>No recurrence of CDI-related diarrhea at 8 weeks following last FMT without the need for an intervention (antibiotics or additional FMT) specifically for recurrence of CDI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of FMT</measure>
    <time_frame>13 weeks</time_frame>
    <description>Evaluate safety of FMT for any serious adverse events up to and including week 13 of receiving FMT for any of the following:&#xD;
Death or a life-threatening event&#xD;
Hospitalization or prolongation of current hospitalization&#xD;
A significant new incapacity to conduct normal life functions</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Clostridium Difficile</condition>
  <arm_group>
    <arm_group_label>Single arm:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients with receive intervention: frozen fecal microbiota transplantation (FMT), kept at -20 oC and will be thawed prior to administration. Patients on antibiotic to control CDI will discontinue antibiotic 24 hours prior to FMT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplant</intervention_name>
    <description>All eligible patients will receive fecal microbiota transplant</description>
    <arm_group_label>Single arm:</arm_group_label>
    <other_name>Human Biotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older.&#xD;
&#xD;
          2. Able to provide informed consent.&#xD;
&#xD;
          3. Laboratory or pathology confirmed diagnosis of recurrent CDI with symptoms (defined&#xD;
             below) within the previous 180 days.&#xD;
&#xD;
          4. ≥ 2 episodes of CDI within 6 months and/or ongoing symptoms consistent with CDI&#xD;
             despite treatment with oral vancomycin at a dose of at least 125 mg 4 times daily for&#xD;
             at least 5 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Planned or actively taking an investigational product for another study.&#xD;
&#xD;
          2. Patients with neutropenia with absolute neutrophil count &lt;0.5 x 109/L&#xD;
&#xD;
          3. Evidence of toxic megacolon or gastrointestinal perforation on abdominal x-ray&#xD;
&#xD;
          4. Peripheral white blood cell count &gt; 30.0 x 109/L AND temperature &gt; 38.0 oC&#xD;
&#xD;
          5. Active gastroenteritis due to Salmonella, Shigella, shiga toxin-producing E. coli,&#xD;
             Yersinia or Campylobacter.&#xD;
&#xD;
          6. Presence of colostomy or ileostomy.&#xD;
&#xD;
          7. Unable to tolerate FMT or enema for any reason.&#xD;
&#xD;
          8. Anticipated requirement for systemic antibiotic therapy for more than 7 days during&#xD;
             the 12 week study period.&#xD;
&#xD;
          9. Actively taking Saccharomyces boulardii or probiotics other than yogurt.&#xD;
&#xD;
         10. No symptoms consistent with CDI, off CDI antibiotic therapy for 3 or more weeks&#xD;
&#xD;
         11. Severe underlying disease such that the patient is not expected to survive for at&#xD;
             least 30 days.&#xD;
&#xD;
         12. Any condition that, in the opinion of the investigator, that the treatment may pose a&#xD;
             health risk to the subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <results_first_submitted>June 2, 2021</results_first_submitted>
  <results_first_submitted_qc>October 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 26, 2021</results_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clostridium Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 1, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02394275/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants must have laboratory diagnosis of recurrent CDI based on Society for Healthcare Epidemiology of America definition, recurrence defined as return of diarrhea and positive stool test after period of symptom resolution within 8 weeks of the first episode and has received at least 10-day course of oral vancomycin.&#xD;
Eligible participants at time of screening will discontinue antibiotic 24 to 48 hours prior to receiving FMT</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Single Arm:</title>
          <description>Eligible patients with receive intervention: frozen fecal microbiota transplantation (FMT), kept at -20 oC and will be thawed prior to administration. Patients on antibiotic to control CDI will discontinue antibiotic 24 hours prior to FMT.&#xD;
Fecal Microbiota Transplant: All eligible patients will receive fecal microbiota transplant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Evaluable at 13 Weeks</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>18 years or older with a history of recurrent CDI</population>
      <group_list>
        <group group_id="B1">
          <title>Single Arm:</title>
          <description>Eligible patients with receive intervention: frozen fecal microbiota transplantation (FMT), kept at -20 oC and will be thawed prior to administration. Patients on antibiotic to control CDI will discontinue antibiotic 24 hours prior to FMT.&#xD;
Fecal Microbiota Transplant: All eligible patients will receive fecal microbiota transplant</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.3" spread="16.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>No Recurrence of CDI-related Diarrhea</title>
        <description>No recurrence of CDI-related diarrhea at 8 weeks following last FMT without the need for an intervention (antibiotics or additional FMT) specifically for recurrence of CDI</description>
        <time_frame>13 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm:</title>
            <description>Eligible patients with receive intervention: frozen fecal microbiota transplantation (FMT), kept at -20 oC and will be thawed prior to administration.&#xD;
Participants on antibiotic to control CDI will discontinue antibiotic 24 - 48 hours hours prior to FMT.&#xD;
Fecal Microbiota Transplant: All eligible patients will receive fecal microbiota transplant</description>
          </group>
        </group_list>
        <measure>
          <title>No Recurrence of CDI-related Diarrhea</title>
          <description>No recurrence of CDI-related diarrhea at 8 weeks following last FMT without the need for an intervention (antibiotics or additional FMT) specifically for recurrence of CDI</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FMT open-label</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety of FMT</title>
        <description>Evaluate safety of FMT for any serious adverse events up to and including week 13 of receiving FMT for any of the following:&#xD;
Death or a life-threatening event&#xD;
Hospitalization or prolongation of current hospitalization&#xD;
A significant new incapacity to conduct normal life functions</description>
        <time_frame>13 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FMT Open-label</title>
            <description>Eligible patients received intervention: frozen fecal microbiota transplantation (FMT), kept at -20 oC and thawed prior to administration. Patients on antibiotic to control CDI will discontinue antibiotic 24 hours prior to FMT.&#xD;
Fecal Microbiota Transplant: All eligible patients received fecal microbiota transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of FMT</title>
          <description>Evaluate safety of FMT for any serious adverse events up to and including week 13 of receiving FMT for any of the following:&#xD;
Death or a life-threatening event&#xD;
Hospitalization or prolongation of current hospitalization&#xD;
A significant new incapacity to conduct normal life functions</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All cause mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE due to cardiac cause</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE due to GI cause</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE due to Infections (recurrent C. difficile)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE due to renal cause</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE due to respiratory cause</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Arm:</title>
          <description>Eligible patients with receive intervention: frozen fecal microbiota transplantation (FMT), kept at -20 oC and will be thawed prior to administration. Patients on antibiotic to control CDI will discontinue antibiotic 24 hours prior to FMT.&#xD;
Fecal Microbiota Transplant: All eligible patients will receive fecal microbiota transplant</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>abdominal cramps, loose bowel movements</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Marek Smieja</name_or_title>
      <organization>St. Joseph's Healthcare Hamilton, ON</organization>
      <phone>905 521 6021</phone>
      <email>smiejam@mcmaster.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

